Abstract

Ordinary acetylcysteine nebulization therapy requires doctors to manually control the nebulizer, which requires professional operation and is unsuitable for large-scale pneumonia prevention and control work. Therefore, this article aimed to explore the application of intelligent medicine combined with acetylcysteine nebulization inhalation in treating neonatal pneumonia, providing a theoretical basis for its clinical application. This article selected 50 newborns with pneumonia from Qiqihar Medical University, Second Affiliated Hospital, to ensure the representativeness and consistency of the sample. Fifty patients with neonatal pneumonia can be randomly divided into groups, with 25 cases in each group. It can ensure the randomness of grouping and reduce the bias of experimental results. In this study, the control group was treated with a single use of acetylcysteine nebulization inhalation. In contrast, the experimental group was treated with intelligent medical technology and acetylcysteine nebulization inhalation. Symptoms, fever, and degree of pulmonary inflammation before and after treatment can be observed. After treatment, the proportion of children with non-inflammation in the experimental and control groups was 46.66 % and 17.9 %, respectively. The proportion of children in the control group with non-inflammatory was 28.76 % lower than that in the experimental group with non-inflammatory. A more comprehensive and scientific evaluation of the application of intelligent medical technology in treating neonatal pneumonia can provide more personalized and efficient treatment plans for similar cases in the future and promote the application of medical technology in neonatal medicine.